40 results on '"Freedman, Neal D."'
Search Results
2. Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions
- Author
-
Purdue, Mark P., Dutta, Diptavo, Machiela, Mitchell J., Gorman, Bryan R., Winter, Timothy, Okuhara, Dayne, Cleland, Sara, Ferreiro-Iglesias, Aida, Scheet, Paul, Liu, Aoxing, Wu, Chao, Antwi, Samuel O., Larkin, James, Zequi, Stênio C., Sun, Maxine, Hikino, Keiko, Hajiran, Ali, Lawson, Keith A., Cárcano, Flavio, Blanchet, Odile, Shuch, Brian, Nepple, Kenneth G., Margue, Gaëlle, Sundi, Debasish, Diver, W. Ryan, Folgueira, Maria A. A. K., van Bokhoven, Adrie, Neffa, Florencia, Brown, Kevin M., Hofmann, Jonathan N., Rhee, Jongeun, Yeager, Meredith, Cole, Nathan R., Hicks, Belynda D., Manning, Michelle R., Hutchinson, Amy A., Rothman, Nathaniel, Huang, Wen-Yi, Linehan, W. Marston, Lori, Adriana, Ferragu, Matthieu, Zidane-Marinnes, Merzouka, Serrano, Sérgio V., Magnabosco, Wesley J., Vilas, Ana, Decia, Ricardo, Carusso, Florencia, Graham, Laura S., Anderson, Kyra, Bilen, Mehmet A., Arciero, Cletus, Pellegrin, Isabelle, Ricard, Solène, Scelo, Ghislaine, Banks, Rosamonde E., Vasudev, Naveen S., Soomro, Naeem, Stewart, Grant D., Adeyoju, Adebanji, Bromage, Stephen, Hrouda, David, Gibbons, Norma, Patel, Poulam, Sullivan, Mark, Protheroe, Andrew, Nugent, Francesca I., Fournier, Michelle J., Zhang, Xiaoyu, Martin, Lisa J., Komisarenko, Maria, Eisen, Timothy, Cunningham, Sonia A., Connolly, Denise C., Uzzo, Robert G., Zaridze, David, Mukeria, Anush, Holcatova, Ivana, Hornakova, Anna, Foretova, Lenka, Janout, Vladimir, Mates, Dana, Jinga, Viorel, Rascu, Stefan, Mijuskovic, Mirjana, Savic, Slavisa, Milosavljevic, Sasa, Gaborieau, Valérie, Abedi-Ardekani, Behnoush, McKay, James, Johansson, Mattias, Phouthavongsy, Larry, Hayman, Lindsay, Li, Jason, Lungu, Ilinca, Bezerra, Stephania M., Souza, Aline G., Sares, Claudia T. G., Reis, Rodolfo B., Gallucci, Fabio P., Cordeiro, Mauricio D., Pomerantz, Mark, Lee, Gwo-Shu M., Freedman, Matthew L., Jeong, Anhyo, Greenberg, Samantha E., Sanchez, Alejandro, Thompson, R. Houston, Sharma, Vidit, Thiel, David D., Ball, Colleen T., Abreu, Diego, Lam, Elaine T., Nahas, William C., Master, Viraj A., Patel, Alpa V., Bernhard, Jean-Christophe, Freedman, Neal D., Bigot, Pierre, Reis, Rui M., Colli, Leandro M., Finelli, Antonio, Manley, Brandon J., Terao, Chikashi, Choueiri, Toni K., Carraro, Dirce M., Houlston, Richard, Eckel-Passow, Jeanette E., Abbosh, Philip H., Ganna, Andrea, Brennan, Paul, Gu, Jian, and Chanock, Stephen J.
- Published
- 2024
- Full Text
- View/download PDF
3. Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma
- Author
-
Gianferante, D. Matthew, Moore, Amy, Spector, Logan G., Wheeler, William, Yang, Tianzhong, Hubbard, Aubrey, Gorlick, Richard, Patiño-Garcia, Ana, Lecanda, Fernando, Flanagan, Adrienne M., Amary, Fernanda, Andrulis, Irene L., Wunder, Jay S., Thomas, David M., Ballinger, Mandy L., Serra, Massimo, Hattinger, Claudia, Demerath, Ellen, Johnson, Will, Birmann, Brenda M., De Vivo, Immaculata, Giles, Graham, Teras, Lauren R., Arslan, Alan, Vermeulen, Roel, Sample, Jeannette, Freedman, Neal D., Huang, Wen-Yi, Chanock, Stephen J., Savage, Sharon A., Berndt, Sonja I., and Mirabello, Lisa
- Published
- 2024
- Full Text
- View/download PDF
4. Transcriptome- and proteome-wide association studies identify genes associated with renal cell carcinoma
- Author
-
Purdue, Mark P., Dutta, Diptavo, Machiela, Mitchell J., Gorman, Bryan R., Winter, Timothy, Okuhara, Dayne, Cleland, Sara, Ferreiro-Iglesias, Aida, Scheet, Paul, Liu, Aoxing, Wu, Chao, Antwi, Samuel O., Larkin, James, Zequi, Stênio C., Sun, Maxine, Hikino, Keiko, Hajiran, Ali, Lawson, Keith A., Cárcano, Flavio, Blanchet, Odile, Shuch, Brian, Nepple, Kenneth G., Margue, Gaëlle, Sundi, Debasish, Diver, W. Ryan, Folgueira, Maria A.A.K., van Bokhoven, Adrie, Neffa, Florencia, Brown, Kevin M., Hofmann, Jonathan N., Rhee, Jongeun, Yeager, Meredith, Cole, Nathan R., Hicks, Belynda D., Manning, Michelle R., Hutchinson, Amy A., Rothman, Nathaniel, Huang, Wen-Yi, Linehan, W. Marston, Lori, Adriana, Ferragu, Matthieu, Zidane-Marinnes, Merzouka, Serrano, Sérgio, Magnabosco, Wesley J., BioBank Japan Project Consortium, Vilas, Ana, Decia, Ricardo, Carusso, Florencia, Graham, Laura S., Anderson, Kyra, Bilen, Mehmet A., Arciero, Cletus, Pellegrin, Isabelle, Ricard, Solène, FinnGen, Scelo, Ghislaine, Banks, Rosamonde E., Vasudev, Naveen S., Soomro, Naeem, Stewart, Grant D., Adeyoju, Adebanji, Bromage, Stephen, Hrouda, David, Gibbons, Norma, Patel, Poulam, Sullivan, Mark, Protheroe, Andrew, Nugent, Francesca I., Fournier, Michelle J., Zhang, Xiaoyu, Martin, Lisa J., Komisarenko, Maria, Eisen, Timothy, Cunningham, Sonia A., Connolly, Denise C., Uzzo, Robert G., Zaridze, David, Mukeria, Anush, Holcatova, Ivana, Hornakova, Anna, Foretova, Lenka, Janout, Vladimir, Mates, Dana, Jinga, Viorel, Rascu, Stefan, Mijuskovic, Mirjana, Savic, Slavisa, Milosavljevic, Sasa, Gaborieau, Valérie, Abedi-Ardekani, Behnoush, McKay, James, Johansson, Mattias, Phouthavongsy, Larry, Hayman, Lindsay, Li, Jason, Lungu, Ilinca, Bezerra, Stephania M., de Souza, Aline G., Sares, Claudia T.G., Reis, Rodolfo B., Gallucci, Fabio P., Cordeiro, Mauricio D., Pomerantz, Mark, Lee, Gwo-Shu M., Freedman, Matthew L., Jeong, Anhyo, Greenberg, Samantha E., Sanchez, Alejandro, Thompson, R. Houston, Sharma, Vidit, Thiel, David D., Ball, Colleen T., Abreu, Diego, Lam, Elaine T., Nahas, William C., Master, Viraj A., Patel, Alpa V., Bernhard, Jean-Christophe, Freedman, Neal D., Bigot, Pierre, Reis, Rui M., Colli, Leandro M., Finelli, Antonio, Manley, Brandon J., Terao, Chikashi, Choueiri, Toni K., Carraro, Dirce M., Houlston, Richard, Eckel-Passow, Jeanette E., Abbosh, Philip H., Ganna, Andrea, Brennan, Paul, Gu, Jian, Chanock, Stephen J., Guo, Xinyu, Winter, Timothy D., Jahagirdar, Om, Ha, Eunji, and Susztak, Katalin
- Published
- 2024
- Full Text
- View/download PDF
5. Volatile organic compounds and mortality from ischemic heart disease: A case-cohort study
- Author
-
Nalini, Mahdi, Poustchi, Hossein, Bhandari, Deepak, Chang, Cindy M., Blount, Benjamin C., Wang, Lanqing, Feng, Jun, Gross, Amy, Khoshnia, Masoud, Pourshams, Akram, Sotoudeh, Masoud, Gail, Mitchell H., Graubard, Barry I., Dawsey, Sanford M, Kamangar, Farin, Boffetta, Paolo, Brennan, Paul, Abnet, Christian C., Malekzadeh, Reza, Freedman, Neal D., and Etemadi, Arash
- Published
- 2024
- Full Text
- View/download PDF
6. Transcriptome-wide association analysis identifies candidate susceptibility genes for prostate-specific antigen levels in men without prostate cancer
- Author
-
Chen, Dorothy M., Dong, Ruocheng, Kachuri, Linda, Hoffmann, Thomas J., Jiang, Yu, Berndt, Sonja I., Shelley, John P., Schaffer, Kerry R., Machiela, Mitchell J., Freedman, Neal D., Huang, Wen-Yi, Li, Shengchao A., Lilja, Hans, Justice, Amy C., Madduri, Ravi K., Rodriguez, Alex A., Van Den Eeden, Stephen K., Chanock, Stephen J., Haiman, Christopher A., Conti, David V., Klein, Robert J., Mosley, Jonathan D., Witte, John S., and Graff, Rebecca E.
- Published
- 2024
- Full Text
- View/download PDF
7. The landscape of rare genetic variants in familial Waldenström macroglobulinemia
- Author
-
Pemov, Alexander, Kim, Jung, Luo, Wen, Liu, Jia, Graham, Cole, Jones, Kristine, DeMangel, Delphine, Freedman, Neal D., Dumontet, Charles, Zhu, Bin, McMaster, Mary L., and Stewart, Douglas R.
- Published
- 2024
- Full Text
- View/download PDF
8. Invited Perspective: Polyaromatic Hydrocarbons in Alcohol--An Unappreciated Carcinogenic Mechanism?
- Author
-
Berrigan, David and Freedman, Neal D.
- Subjects
Meat ,Polycyclic aromatic hydrocarbons ,Environmental issues ,Health - Abstract
Polycyclic aromatic hydrocarbons (PAHs) are a large class of organic compounds produced by the incomplete combustion of fossil fuels as well as from high heat applied to organic matter such [...]
- Published
- 2024
- Full Text
- View/download PDF
9. Age-specific cancer mortality in the U.S. during the COVID-19 pandemic, March-December 2020
- Author
-
Shiels, Meredith S., primary, Haque, Anika T., additional, Freedman, Neal D., additional, Kim, Hae-Rin, additional, Berrington de González, Amy, additional, and Albert, Paul S., additional
- Published
- 2024
- Full Text
- View/download PDF
10. Age-Specific Cancer Mortality in the US During the COVID-19 Pandemic, March to December 2020.
- Author
-
Shiels, Meredith S., Haque, Anika T., Freedman, Neal D., Hae-Rin Kim, de González, Amy Berrington, and Albert, Paul S.
- Abstract
Background: It is important to understand the impact of the COVID-19 pandemic on cancer death rates in 2020 in the US. We estimated whether there were larger-than-expected changes in cancer mortality rates from March to December 2020 after accounting for temporal and seasonal patterns using data from January 2011 to February 2020 by cancer type and age. Methods: We obtained death counts and underlying causes of death by cancer type, month/year (2011-2020), and age group from the National Center for Health Statistics and population estimates from the US Census Bureau. Poisson regression was used to test for significant changes in cancer death rates from March to December 2020 compared with prior years. Results: After accounting for temporal trends and seasonal patterns, total cancer death rates were significantly lower than expected during March to December 2020 among 55- to 64-year-olds and =75-year-olds, but not in other age groups. Cancer death rates were 2% lower than expected from March to June among 55- to 64-year-olds and 2% to 3% lower from March to July and December among =75-year-olds. Among =75-year-olds, colorectal cancer death rates were lower from March to June [rate ratios (RR) = 0.94-0.96; P < 0.05]; however, lung cancer death rates were 5% lower across each month (all RRs = 0.95; P < 0.05). Conclusions: In the US, cancer death rates based on the underlying cause of death were broadly similar to expected rates from March to December 2020. However, cancer death rates were lower than expected among 55- to 64-year-olds and =75-year-olds, likely due to COVID-19 as a competing cause of death. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Supplementary Methods and Materials from Unveiling an Association between Waterpipe Smoking and Bladder Cancer Risk: A Multicenter Case–Control Study in Iran
- Author
-
Hadji, Maryam, primary, Rashidian, Hamideh, primary, Marzban, Maryam, primary, Rezaianzadeh, Abbas, primary, Ansari-Moghaddam, Alireza, primary, Bakhshi, Mahdieh, primary, Nejatizadeh, Azim, primary, Seyyedsalehi, Monireh Sadat, primary, Naghibzadeh-Tahami, Ahmad, primary, Haghdoost, AliAkbar, primary, Mohebbi, Elham, primary, Freedman, Neal D., primary, Malekzadeh, Reza, primary, Etemadi, Arash, primary, Kamangar, Farin, primary, Weiderpass, Elisabete, primary, Pukkala, Eero, primary, Boffetta, Paolo, primary, and Zendehdel, Kazem, primary
- Published
- 2024
- Full Text
- View/download PDF
12. Data from Unveiling an Association between Waterpipe Smoking and Bladder Cancer Risk: A Multicenter Case–Control Study in Iran
- Author
-
Hadji, Maryam, primary, Rashidian, Hamideh, primary, Marzban, Maryam, primary, Rezaianzadeh, Abbas, primary, Ansari-Moghaddam, Alireza, primary, Bakhshi, Mahdieh, primary, Nejatizadeh, Azim, primary, Seyyedsalehi, Monireh Sadat, primary, Naghibzadeh-Tahami, Ahmad, primary, Haghdoost, AliAkbar, primary, Mohebbi, Elham, primary, Freedman, Neal D., primary, Malekzadeh, Reza, primary, Etemadi, Arash, primary, Kamangar, Farin, primary, Weiderpass, Elisabete, primary, Pukkala, Eero, primary, Boffetta, Paolo, primary, and Zendehdel, Kazem, primary
- Published
- 2024
- Full Text
- View/download PDF
13. Severe housing cost burden and premature mortality from cancer
- Author
-
Lawrence, Wayne R, primary, Freedman, Neal D, additional, McGee-Avila, Jennifer K, additional, Mason, Lee, additional, Chen, Yingxi, additional, Ewing, Aldenise P, additional, and Shiels, Meredith S, additional
- Published
- 2024
- Full Text
- View/download PDF
14. Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants
- Author
-
Jenkins, David J A, primary, Willett, Walter C, additional, Yusuf, Salim, additional, Hu, Frank B, additional, Glenn, Andrea J, additional, Liu, Simin, additional, Mente, Andrew, additional, Miller, Victoria, additional, Bangdiwala, Shrikant I, additional, Gerstein, Hertzel C, additional, Sieri, Sabina, additional, Ferrari, Pietro, additional, Patel, Alpa V, additional, McCullough, Marjorie L, additional, Le Marchand, Loïc, additional, Freedman, Neal D, additional, Loftfield, Erikka, additional, Sinha, Rashmi, additional, Shu, Xiao-Ou, additional, Touvier, Mathilde, additional, Sawada, Norie, additional, Tsugane, Shoichiro, additional, van den Brandt, Piet A, additional, Shuval, Kerem, additional, Khan, Tauseef Ahmad, additional, Paquette, Melanie, additional, Sahye-Pudaruth, Sandhya, additional, Patel, Darshna, additional, Siu, Teenie Fei Yi, additional, Srichaikul, Korbua, additional, Kendall, Cyril W C, additional, Sievenpiper, John L, additional, Balachandran, Bashyam, additional, Zurbau, Andreea, additional, Wang, Xunan, additional, Liang, Fred, additional, and Yang, Wanning, additional
- Published
- 2024
- Full Text
- View/download PDF
15. Outdoor Ultrafine Particulate Matter and Risk of Lung Cancer in Southern California
- Author
-
IRAS OH Epidemiology Chemical Agents, IRAS – One Health Chemical, Jones, Rena R, Fisher, Jared A, Hasheminassab, Sina, Kaufman, Joel D, Freedman, Neal D, Ward, Mary H, Sioutas, Constantinos, Vermeulen, Roel, Hoek, Gerard, Silverman, Debra T, IRAS OH Epidemiology Chemical Agents, IRAS – One Health Chemical, Jones, Rena R, Fisher, Jared A, Hasheminassab, Sina, Kaufman, Joel D, Freedman, Neal D, Ward, Mary H, Sioutas, Constantinos, Vermeulen, Roel, Hoek, Gerard, and Silverman, Debra T
- Published
- 2024
16. Prevalence and Incidence of Metabolic Syndrome and Its Components Among Waterpipe Users.
- Author
-
Sadeghi, Yasaman, Naghash, Mahdokht, Poustchi, Hossein, Alvand, Saba, Gandomkar, Abdullah, Vardanjani, Hossein Molavi, Malekzadeh, Fatemeh, Boffetta, Paolo, Abnet, Christian C., Freedman, Neal D., Malekzadeh, Reza, and Etemadi, Arash
- Subjects
METABOLIC syndrome ,FASTING ,HDL cholesterol ,SMOKING cessation ,BLOOD sugar ,WAIST circumference - Abstract
Objectives: To determine the associations between waterpipe use, duration, and intensity of use with prevalence and incidence of metabolic syndrome and its components (increased waist circumference, triglycerides, fasting glucose, blood pressure and decreased high-density lipoprotein cholesterol). Methods: We conducted cross-sectional and prospective analyses using data from the Pars Cohort Study in southern Iran, encompassing 9,264 participants at the baseline, and 5,002 randomly selected in a repeated follow-up. We used multivariate logistic regression models adjusted for age, sex, education, wealth score, physical activity and cigarette pack-years to report odds ratios (OR) and 95% confidence intervals (CI). Results: Among 9,264 participants, 3,119 (33.7%) had metabolic syndrome, and 3,482 (37.6%) had ever smoked waterpipe, with both more common in women than in men. In adjusted models, former waterpipe use was significantly associated with prevalence (OR = 1.43, 95% CI: 1.23–1.68) and incidence (OR = 1.57, 95% CI: 1.19–2.06) of the metabolic syndrome while current waterpipe use was not. Past use was associated with increased risk in all components of metabolic syndrome; current use was associated with increases in all except high blood glucose and hypertension. Past waterpipe users had higher waterpipe use intensity (before quitting) in comparison with current users (2.3 vs. 2.0 waterpipes per day, p < 0.01) and had started waterpipe smoking at a younger age (27.2 vs. 30.1 years, p < 0.01). Conclusion: Waterpipe use was associated with metabolic syndrome and its components, especially among former users potentially due to higher intensity and earlier initiation of use. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Altered salivary microbiota associated with high-sugar beverage consumption.
- Author
-
Fan, Xiaozhou, Monson, Kelsey R., Peters, Brandilyn A., Whittington, Jennifer M., Um, Caroline Y., Oberstein, Paul E., McCullough, Marjorie L., Freedman, Neal D., Huang, Wen-Yi, Ahn, Jiyoung, and Hayes, Richard B.
- Subjects
BEVERAGE consumption ,SUGAR content of beverages ,HUMAN microbiota ,LACTOBACILLUS rhamnosus ,DENTAL plaque ,BEVERAGES - Abstract
The human oral microbiome may alter oral and systemic disease risk. Consuming high sugar content beverages (HSB) can lead to caries development by altering the microbial composition in dental plaque, but little is known regarding HSB-specific oral microbial alterations. Therefore, we conducted a large, population-based study to examine associations of HSB intake with oral microbiome diversity and composition. Using mouthwash samples of 989 individuals in two nationwide U.S. cohorts, bacterial 16S rRNA genes were amplified, sequenced, and assigned to bacterial taxa. HSB intake was quantified from food frequency questionnaires as low (< 1 serving/week), medium (1–3 servings/week), or high (> 3 servings/week). We assessed overall bacterial diversity and presence of specific taxa with respect to HSB intake in each cohort separately and combined in a meta-analysis. Consistently in the two cohorts, we found lower species richness in high HSB consumers (> 3 cans/week) (p = 0.027), and that overall bacterial community profiles differed from those of non-consumers (PERMANOVA p = 0.040). Specifically, presence of a network of commensal bacteria (Lachnospiraceae, Peptostreptococcaceae, and Alloprevotella rava) was less common in high compared to non-consumers, as were other species including Campylobacter showae, Prevotella oulorum, and Mycoplasma faucium. Presence of acidogenic bacteria Bifodobacteriaceae and Lactobacillus rhamnosus was more common in high consumers. Abundance of Fusobacteriales and its genus Leptotrichia, Lachnoanaerobaculum sp., and Campylobacter were lower with higher HSB consumption, and their abundances were correlated. No significant interaction was found for these associations with diabetic status or with microbial markers for caries (S. mutans) and periodontitis (P. gingivalis). Our results suggest that soft drink intake may alter the salivary microbiota, with consistent results across two independent cohorts. The observed perturbations of overrepresented acidogenic bacteria and underrepresented commensal bacteria in high HSB consumers may have implications for oral and systemic disease risk. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Association of tea and coffee consumption and biliary tract cancer risk: The Biliary Tract Cancers Pooling Project.
- Author
-
Yu-Han Huang, Loftfield, Erikka, Argirion, Ilona, Adami, Hans-Olov, Albanes, Demetrius, Chan, Andrew T., Fedirko, Veronika, Fraser, Gary E., Freedman, Neal D., Giles, Graham G., Hartge, Patricia, Katzke, Verena, Knutsen, Synnove F., Lacey Jr, James, Liao, Linda M., Juhua Luo, Milne, Roger L., O'Brien, Katie M., Peters, Ulrike, and Poynter, Jenny N.
- Published
- 2024
- Full Text
- View/download PDF
19. Changes in smoking use and subsequent lung cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study.
- Author
-
Gutiérrez-Torres, Daniela S, Kim, Sungduk, Albanes, Demetrius, Weinstein, Stephanie J, Inoue-Choi, Maki, Albert, Paul S, and Freedman, Neal D
- Subjects
LUNG cancer ,CANCER prevention ,SMOKING ,DISEASE risk factors ,BETA carotene - Abstract
Background Reducing cigarettes per day may lower the risk of lung cancer compared with continuing to smoke at the same intensity. Other changes in smoking behaviors, such as increasing cigarette consumption or quitting for a period and relapsing, may also affect lung cancer risk. Methods We examined changes in smoking status and cigarettes per day among 24 613 Finnish male smokers aged 50-69 years who participated in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Longitudinal data on smoking were collected during study follow-up visits 3 times a year (approximately every 4 months) between 1985 and 1993. Incident lung cancer patients through 2012 were identified by the Finnish Cancer Registry. Risk ratios (RRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression. Results Compared with smoking 20 cigarettes per day continuously across the intervention period, reducing an average of 5 cigarettes per day per year while smoking was associated with a 20% lower risk of lung cancer (95% CI = 0.71 to 0.90). A substantially lower risk of lung cancer was also observed when participants smoked at 50% (RR = 0.72, 95% CI = 0.57 to 0.90) and 10% (RR = 0.55, 95% CI = 0.36 to 0.83) of study visits, relative to smoked at 100% of study visits. Conclusions Smokers may lower their risk of lung cancer by reducing smoking intensity (cigarettes per day while smoking) and the time they smoke. However, quitting smoking completely is the most effective way for smokers to reduce their risk of lung cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Trends in smoking-attributable and smoking-unrelated lung cancer death rates in the United States, 1991-2018.
- Author
-
Shiels, Meredith S, Graubard, Barry I, McNeel, Timothy S, Kahle, Lisa, and Freedman, Neal D
- Subjects
LUNG cancer ,DEATH rate ,PASSIVE smoking ,AIR pollution ,SMOKING - Abstract
Background In the United States, lung cancer death rates have been declining for decades, primarily as a result of pronounced decreases in cigarette smoking. It is unclear, however, whether there have been similar declines in mortality rates of lung cancer unrelated to smoking. We estimated trends in US lung cancer death rates attributable and not attributable to smoking from 1991 to 2018. Methods The study included 30- to 79-year-olds in the National Health Interview Survey who were linked to the National Death Index, 1991-2014. Adjusted hazard ratios for smoking status and lung cancer death were estimated, and age-specific population attributable fractions were calculated. Annual population attributable fractions were multiplied by annual US national lung cancer mortality, partitioning rates into smoking-attributable and smoking-unrelated lung cancer deaths. All statistical tests were 2-sided. Results During 1991-2018, the proportion of never smokers increased among both men (35.1%-54.6%) and women (54.0%-65.4%). Compared with those who had ever smoked, those who had never smoked had 86% lower risk (hazard ratio = 0.14; 95% confidence interval [CI] = 0.12 to 0.16) of lung cancer death. The fraction of lung cancer deaths attributable to smoking decreased from 81.4% (95% CI = 78.9 to 81.4) to 74.7% (95% CI = 78.1 to 71.4). Smoking-attributable lung cancer death rates declined 2.7% per year (95% CI = ‒2.9% to ‒2.5%) and smoking-unrelated lung cancer death rates declined 1.8% per year (95% CI = ‒2.0% to ‒1.5%); these declines have accelerated in recent years. Conclusions An increasing proportion of lung cancer deaths are unrelated to smoking based on declines in smoking prevalence. Smoking-unrelated lung cancer death rates have declined, however, perhaps because of decreases in secondhand smoke and air pollution exposure as well as treatment improvements. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Unveiling an Association between Waterpipe Smoking and Bladder Cancer Risk: A Multicenter Case–Control Study in Iran
- Author
-
Hadji, Maryam, primary, Rashidian, Hamideh, additional, Marzban, Maryam, additional, Rezaianzadeh, Abbas, additional, Ansari-Moghaddam, Alireza, additional, Bakhshi, Mahdieh, additional, Nejatizadeh, Azim, additional, Seyyedsalehi, Monireh Sadat, additional, Naghibzadeh-Tahami, Ahmad, additional, Haghdoost, AliAkbar, additional, Mohebbi, Elham, additional, Freedman, Neal D., additional, Malekzadeh, Reza, additional, Etemadi, Arash, additional, Kamangar, Farin, additional, Weiderpass, Elisabete, additional, Pukkala, Eero, additional, Boffetta, Paolo, additional, and Zendehdel, Kazem, additional
- Published
- 2024
- Full Text
- View/download PDF
22. Lung cancer statistics, 2023.
- Author
-
Kratzer, Tyler B., Bandi, Priti, Freedman, Neal D., Smith, Robert A., Travis, William D., Jemal, Ahmedin, and Siegel, Rebecca L.
- Subjects
LUNG cancer ,PATIENT Protection & Affordable Care Act ,HEALTH services accessibility - Abstract
Despite decades of declining mortality rates, lung cancer remains the leading cause of cancer death in the United States. This article examines lung cancer incidence, stage at diagnosis, survival, and mortality using population‐based data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries. Over the past 5 years, declines in lung cancer mortality became considerably greater than declines in incidence among men (5.0% vs. 2.6% annually) and women (4.3% vs. 1.1% annually), reflecting absolute gains in 2‐year relative survival of 1.4% annually. Improved outcomes likely reflect advances in treatment, increased access to care through the Patient Protection and Affordable Care Act, and earlier stage diagnosis; for example, compared with a 4.6% annual decrease for distant‐stage disease incidence during 2013–2019, the rate for localized‐stage disease rose by 3.6% annually. Localized disease incidence increased more steeply in states with the highest lung cancer screening prevalence (by 3%–5% annually) than in those with the lowest (by 1%–2% annually). Despite progress, disparities remain. For example, Native Americans have the highest incidence and the slowest decline (less than 1% annually among men and stagnant rates among women) of any group. In addition, mortality rates in Mississippi and Kentucky are two to three times higher than in most western states, largely because of elevated historic smoking prevalence that remains. Racial and geographic inequalities highlight longstanding opportunities for more concerted tobacco‐control efforts targeted at high‐risk populations, including improved access to smoking‐cessation treatments and lung cancer screening, as well as state‐of‐the‐art treatment. Recent declines in lung cancer mortality have outpaced those for incidence, reflecting gains in relative survival that are partly due to recent shifts to earlier stage at diagnosis. Persistent racial and geographic disparities reflect longstanding opportunities for public health intervention to reduce smoking and improve health care access. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Opioid use in cancer patients compared with noncancer pain patients in a veteran population.
- Author
-
Mudumbai, Seshadri C, He, Han, Chen, Ji-Qing, Kapoor, Aditi, Regala, Samantha, Mariano, Edward R, Stafford, Randall S, Abnet, Christian C, Pfeiffer, Ruth M, Freedman, Neal D, and Etemadi, Arash
- Subjects
OPIOIDS ,CANCER patient care ,CANCER pain - Abstract
Background Opioid safety initiatives may secondarily impact opioid prescribing and pain outcomes for cancer care. Methods We reviewed electronic health record data at a tertiary Veterans Affairs system (VA Palo Alto) for all patients from 2015 to 2021. We collected outpatient Schedule II opioid prescriptions data and calculated morphine milligram equivalents (MMEs) using Centers for Disease Control and Prevention conversion formulas. To determine the clinical impact of changes in opioid prescription, we used the highest level of pain reported by each patient on the 0-to-10 Numeric Rating Scale in each year, categorized into mild (0-3), moderate (4-6), and severe (7 and above). Results Among 89 569 patients, 9073 had a cancer diagnosis. Cancer patients were almost twice as likely to have an opioid prescription compared with noncancer patients (69.0% vs 36.7%, respectively). The proportion of patients who received an opioid prescription decreased from 27.1% to 18.1% (trend P < .01) in cancer patients and from 17.0% to 10.2% in noncancer patients (trend P < .01). Cancer and noncancer patients had similar declines of MMEs per year between 2015 and 2019, but the decline was more rapid for cancer patients (1462.5 to 946.4, 35.3%) compared with noncancer patients (1315.6 to 927.7, 29.5%) from 2019 to 2021. During the study period, the proportion of noncancer patients who experienced severe pain was almost unchanged, whereas it increased among cancer patients, reaching a significantly higher rate than among noncancer patients in 2021 (31.9% vs 27.4%, P < .01). Conclusions Our findings suggest potential unintended consequences for cancer care because of efforts to manage opioid-related risks. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Risk model‐based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.
- Author
-
Choi, Eunji, Luo, Sophia J., Ding, Victoria Y., Wu, Julie T., Kumar, Ashok V., Wampfler, Jason, Tammemägi, Martin C., Wilkens, Lynne R., Aredo, Jacqueline V., Backhus, Leah M., Neal, Joel W., Leung, Ann N., Freedman, Neal D., Hung, Rayjean J., Amos, Christopher I., Le Marchand, Loïc, Cheng, Iona, Wakelee, Heather A., Yang, Ping, and Han, Summer S.
- Subjects
LUNG cancer ,CANCER survivors ,RECEIVER operating characteristic curves ,PREDICTION models - Abstract
Background: Recent therapeutic advances and screening technologies have improved survival among patients with lung cancer, who are now at high risk of developing second primary lung cancer (SPLC). Recently, an SPLC risk‐prediction model (called SPLC‐RAT) was developed and validated using data from population‐based epidemiological cohorts and clinical trials, but real‐world validation has been lacking. The predictive performance of SPLC‐RAT was evaluated in a hospital‐based cohort of lung cancer survivors. Methods: The authors analyzed data from 8448 ever‐smoking patients diagnosed with initial primary lung cancer (IPLC) in 1997–2006 at Mayo Clinic, with each patient followed for SPLC through 2018. The predictive performance of SPLC‐RAT and further explored the potential of improving SPLC detection through risk model‐based surveillance using SPLC‐RAT versus existing clinical surveillance guidelines. Results: Of 8448 IPLC patients, 483 (5.7%) developed SPLC over 26,470 person‐years. The application of SPLC‐RAT showed high discrimination area under the receiver operating characteristics curve: 0.81). When the cohort was stratified by a 10‐year risk threshold of ≥5.6% (i.e., 80th percentile from the SPLC‐RAT development cohort), the observed SPLC incidence was significantly elevated in the high‐risk versus low‐risk subgroup (13.1% vs. 1.1%, p < 1 × 10–6). The risk‐based surveillance through SPLC‐RAT (≥5.6% threshold) outperformed the National Comprehensive Cancer Network guidelines with higher sensitivity (86.4% vs. 79.4%) and specificity (38.9% vs. 30.4%) and required 20% fewer computed tomography follow‐ups needed to detect one SPLC (162 vs. 202). Conclusion: In a large, hospital‐based cohort, the authors validated the predictive performance of SPLC‐RAT in identifying high‐risk survivors of SPLC and showed its potential to improve SPLC detection through risk‐based surveillance. Plain Language Summary: Lung cancer survivors have a high risk of developing second primary lung cancer (SPLC).However, no evidence‐based guidelines for SPLC surveillance are available for lung cancer survivors.Recently, an SPLC risk‐prediction model was developed and validated using data from population‐based epidemiological cohorts and clinical trials, but real‐world validation has been lacking.Using a large, real‐world cohort of lung cancer survivors, we showed the high predictive accuracy and risk‐stratification ability of the SPLC risk‐prediction model.Furthermore, we demonstrated the potential to enhance efficiency in detecting SPLC using risk model‐based surveillance strategies compared to the existing consensus‐based clinical guidelines, including the National Comprehensive Cancer Network. Given the rapidly growing number of lung cancer survivors who are now at high risk of developing second primary lung cancer (SPLC), previous studies have identified SPLC risk factors and developed SPLC risk‐prediction models, but they lack insight into real‐world validation to help improve clinical decision‐making in SPLC surveillance for lung cancer survivors. Using a large, hospital‐based real‐world cohort of lung cancer survivors, the authors validated the predictive accuracy of an SPLC risk‐prediction model (area under the curve of 0.81), that can identify high‐risk lung cancer survivors for SPLC and can be incorporated into clinical decision‐making for SPLC surveillance to improve the systematic management of lung cancer survivors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Outdoor Ultrafine Particulate Matter and Risk of Lung Cancer in Southern California.
- Author
-
Jones, Rena R., Fisher, Jared A., Hasheminassab, Sina, Kaufman, Joel D., Freedman, Neal D., Ward, Mary H., Sioutas, Constantinos, Vermeulen, Roel, Hoek, Gerard, and Silverman, Debra T.
- Subjects
PARTICULATE matter ,LUNG cancer ,DISEASE risk factors ,PROPORTIONAL hazards models ,SMALL cell carcinoma - Abstract
Rationale: Particulate matter ≤2.5 μm in aerodynamic diameter (PM2.5) is an established cause of lung cancer, but the association with ultrafine particulate matter (UFP; aerodynamic diameter < 0.1 μm) is unclear. Objectives: To investigate the association between UFP and lung cancer overall and by histologic subtype. Methods: The Los Angeles Ultrafines Study includes 45,012 participants aged ≤50 years in southern California at enrollment (1995-1996) followed through 2017 for incident lung cancer (n = 1,770). We estimated historical residential ambient UFP number concentrations via land use regression and back extrapolation using PM
2.5 . In Cox proportional hazards models adjusted for smoking and other confounders, we estimated associations between 10-year lagged UFP (per 10,000 particles/cm³ and quartiles) and lung cancer overall and by major histologic subtype (adenocarcinoma, squamous cell carcinoma, and small cell carcinoma). We also evaluated relationships by smoking status, birth cohort, and historical duration at the residence. Measurements and Main Results: UFP was modestly associated with lung cancer risk overall (hazard ratio [HR], 1.03 [95% confidence interval (CI), 0.99-1.08]). For adenocarcinoma, we observed a positive trend among men; risk was increased in the highest exposure quartile versus the lowest (HR, 1.39 [95% CI, 1.05-1.85]; P for trend = 0.01) and was also increased in continuous models (HR per 10,000 particles/cm3, 1.09 [95% CI, 1.00-1.18]), but no increased risk was apparent among women (P for interaction = 0.03). Adenocarcinoma risk was elevated among men born between 1925 and 1930 (HR, 1.13 [95% CI, 1.02-1.26] per 10,000) but not for other birth cohorts, and was suggestive for men with ≤10 years of residential duration (HR, 1.11 [95% CI, 0.98-1.26]). We found no consistent associations for women or other histologic subtypes. Conclusions: UFP exposure was modestly associated with lung cancer overall, with stronger associations observed for adenocarcinoma of the lung. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
26. Association of hormonal and reproductive factors with differentiated thyroid cancer risk in women: a pooled prospective cohort analysis.
- Author
-
O'Grady, Thomas J, Rinaldi, Sabina, Michels, Kara A, Adami, Hans-Olov, Buring, Julie E, Chen, Yu, Clendenen, Tess V, D'Aloisio, Aimee, DeHart, Jessica Clague, Franceschi, Silvia, Freedman, Neal D, Gierach, Gretchen L, Giles, Graham G, Lacey, James V, Lee, I-Min, Liao, Linda M, Linet, Martha S, McCullough, Marjorie L, Patel, Alpa V, and Prizment, Anna
- Subjects
MENARCHE ,ORAL contraceptives ,CONTRACEPTION ,THYROID cancer ,DISEASE risk factors ,SEX hormones ,COHORT analysis ,PROPORTIONAL hazards models - Abstract
Background The incidence of differentiated thyroid cancer (DTC) is higher in women than in men but whether sex steroid hormones contribute to this difference remains unclear. Studies of reproductive and hormonal factors and thyroid cancer risk have provided inconsistent results. Methods Original data from 1 252 907 women in 16 cohorts in North America, Europe, Australia and Asia were combined to evaluate associations of DTC risk with reproductive and hormonal factors. Multivariable-adjusted Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% CIs. Results During follow-up, 2142 women were diagnosed with DTC. Factors associated with higher risk of DTC included younger age at menarche (<10 vs 10–11 years; HR, 1.28; 95% CI, 1.00–1.64), younger (<40; HR, 1.31; 95% CI, 1.05–1.62) and older (≥55; HR, 1.33; 95% CI, 1.05–1.68) ages at menopause (vs 40–44 years), ever use of menopausal hormone therapy (HR, 1.16; 95% CI, 1.02–1.33) and previous hysterectomy (HR, 1.25; 95% CI, 1.13–1.39) or bilateral oophorectomy (HR, 1.14; 95% CI, 1.00–1.29). Factors associated with lower risk included longer-term use (≥5 vs <5 years) of oral contraceptives (HR, 0.86; 95% CI, 0.76–0.96) among those who ever used oral contraception and baseline post-menopausal status (HR, 0.82; 95% CI, 0.70–0.96). No associations were observed for parity, duration of menopausal hormone therapy use or lifetime number of reproductive years or ovulatory cycles. Conclusions Our study provides some evidence linking reproductive and hormonal factors with risk of DTC. Results should be interpreted cautiously considering the modest strength of the associations and potential for exposure misclassification and detection bias. Prospective studies of pre-diagnostic circulating sex steroid hormone measurements and DTC risk may provide additional insight. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Helicobacter hepaticus and Helicobacter bilis in liver and biliary cancers from ATBC and PLCO.
- Author
-
Murphy, Gwen, Freedman, Neal D., Abnet, Christian C., Albanes, Demetrius, Cross, Amanda J., Huang, Wen‐Yi, Koshiol, Jill, McGlynn, Katherine, Parisi, Dominick, Männistö, Satu, Weinstein, Stephanie J., Waterboer, Tim, and Butt, Julia
- Abstract
Background: Helicobacter species (spp.) have been detected in human bile and hepatobiliary tissue Helicobacter spp. promote gallstone formation and hepatobiliary tumors in laboratory studies, though it remains unclear whether Helicobacter spp. contribute to these cancers in humans. We used a multiplex panel to assess whether seropositivity to Helicobacter (H.) hepaticus or H. bilis proteins was associated with the development of hepatobiliary cancers in the Finnish Alpha‐Tocopherol, Beta‐Carotene Cancer Prevention (ATBC) Study, and US‐based Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). Methods: We included 62 biliary and 121 liver cancers, and 190 age‐matched controls from ATBC and 74 biliary and 105 liver cancers, and 364 age‐ and sex‐matched controls from PLCO. Seropositivity to 14 H. hepaticus and H. bilis antigens was measured using a multiplex assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were adjusted for major hepatobiliary cancer risk factors and Helicobacter pylori serostatus. Results: Seropositivity to the H. bilis antigen, P167D, was associated with more than a twofold higher risk of liver cancer (OR: 2.38; 95% CI: 1.06, 5.36) and seropositivity to the H. hepaticus antigens HH0407 or HH1201, or H. bilis antigen, HRAG 01470 were associated with higher risk of biliary cancer (OR: 5.01; 95% CI: 1.53, 16.40; OR: 2.40; 95% CI: 1.00, 5.76; OR: 3.27; 95% CI: 1.14, 9.34, respectively) within PLCO. No associations for any of the H. hepaticus or H. bilis antigens were noted for liver or biliary cancers within ATBC. Conclusions: Further investigations in cohort studies should examine the role of Helicobacter spp. in the etiology of liver and biliary cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Ambient fine particulate matter and breast cancer incidence in a large prospective US cohort.
- Author
-
White, Alexandra J, Fisher, Jared A, Sweeney, Marina R, Freedman, Neal D, Kaufman, Joel D, Silverman, Debra T, and Jones, Rena R
- Subjects
PARTICULATE matter ,BREAST cancer ,WATERSHEDS ,AIR pollutants ,ESTROGEN receptors ,HORMONE receptor positive breast cancer - Abstract
Background Fine particulate matter (PM
2.5 ) has been inconsistently associated with breast cancer incidence, however, few studies have considered historic exposure when levels were higher. Methods Outdoor residential PM2.5 concentrations were estimated using a nationwide spatiotemporal model for women in the National Institutes of Health–AARP Diet and Health Study, a prospective cohort located in 6 states (California, Florida, Louisiana, New Jersey, North Carolina, and Pennsylvania) and 2 metropolitan areas (Atlanta, GA, and Detroit, MI) and enrolled in 1995-1996 (n = 196 905). Annual average PM2.5 concentrations were estimated for a 5-year historical period 10 years prior to enrollment (1980-1984). We used Cox regression to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between a 10 µg/m3 increase in PM2.5 and breast cancer incidence overall and by estrogen receptor status and catchment area. Results With follow-up of participants through 2017, a total of 15 870 breast cancer cases were identified. A 10 ug/m3 increase in PM2.5 was statistically significantly associated with overall breast cancer incidence (HR = 1.08, 95% CI = 1.02 to 1.13). The association was evident for estrogen receptor–positive (HR = 1.10, 95% CI = 1.04 to 1.17) but not estrogen receptor–negative tumors (HR = 0.97, 95% CI = 0.84 to 1.13; Pheterogeneity = .3). Overall breast cancer hazard ratios were more than 1 across the catchment areas, ranging from a hazard ratio of 1.26 (95% CI = 0.96 to 1.64) for North Carolina to a hazard ratio of 1.04 (95% CI = 0.68 to 1.57) for Louisiana (Pheterogeneity = .9). Conclusions In this large US cohort with historical air pollutant exposure estimates, PM2.5 was associated with risk of estrogen receptor–positive breast cancer. State-specific estimates were imprecise but suggest that future work should consider region-specific associations and the potential contribution of PM2.5 chemical constituency in modifying the observed association. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
29. Neighborhood Socioeconomic Disadvantage Across the Life Course and Premature Mortality.
- Author
-
Lawrence, Wayne R., Kucharska-Newton, Anna M., Magnani, Jared W., Brewer, LaPrincess C., Shiels, Meredith S., George, Kristen M., Lutsey, Pamela L., Jenkins, Brittany D., Sullivan, Kevin J., Carson, April P., and Freedman, Neal D.
- Published
- 2024
- Full Text
- View/download PDF
30. Multivitamin Use and Mortality Risk in 3 Prospective US Cohorts.
- Author
-
Loftfield, Erikka, O'Connell, Caitlin P., Abnet, Christian C., Graubard, Barry I., Liao, Linda M., Beane Freeman, Laura E., Hofmann, Jonathan N., Freedman, Neal D., and Sinha, Rashmi
- Published
- 2024
- Full Text
- View/download PDF
31. Alu retroelement copy number and lung cancer risk in the prospective Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial
- Author
-
Wong, Jason Y.Y., Cawthon, Richard, Hu, Wei, Ezennia, Somayina, Gadalla, Shahinaz M., Breeze, Charles, Blechter, Batel, Freedman, Neal D., Huang, Wen-Yi, Hosgood, H. Dean, Seow, Wei Jie, Bassig, Bryan A., Rahman, Mohammad, Hayes, Richard B., Rothman, Nathaniel, and Lan, Qing
- Published
- 2024
- Full Text
- View/download PDF
32. Erratum: "Moving toward findable, accessible, interoperable, reusable practices in epidemiologic research".
- Author
-
García-Closas M, Ahearn TU, Gaudet MM, Hurson AN, Balasubramanian JB, Choudhury PP, Gerlanc NM, Patel B, Russ D, Abubakar M, Freedman ND, Wong WSW, Chanock SJ, de Gonzalez AB, and Almeida JS
- Published
- 2024
- Full Text
- View/download PDF
33. Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer.
- Author
-
Kwak S, Wang C, Usyk M, Wu F, Freedman ND, Huang WY, McCullough ML, Um CY, Shrubsole MJ, Cai Q, Li H, Ahn J, and Hayes RB
- Abstract
Importance: The oral microbiota may be involved in development of head and neck squamous cell cancer (HNSCC), yet current evidence is largely limited to bacterial 16S amplicon sequencing or small retrospective case-control studies., Objective: To test whether oral bacterial and fungal microbiomes are associated with subsequent risk of HNSCC development., Design, Setting, and Participants: Prospective nested case-control study among participants providing oral samples in 3 epidemiological cohorts, the American Cancer Society Cancer Prevention Study II Nutrition Cohort, the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, and the Southern Community Cohort Study. Two hundred thirty-six patients who prospectively developed HNSCC were identified during a mean (SD) of 5.1 (3.6) years of follow-up. Control participants who remained HNSCC free were selected by 2:1 frequency matching on cohort, age, sex, race and ethnicity, and time since oral sample collection. Data analysis was conducted in 2023., Exposures: Characterization of the oral bacterial microbiome using whole-genome shotgun sequencing and the oral fungal microbiome using internal transcribed spacer sequencing. Association of bacterial and fungal taxa with HNSCC was assessed by analysis of compositions of microbiomes with bias correction. Association with red and orange oral pathogen complexes was tested by logistic regression. A microbial risk score for HNSCC risk was calculated from risk-associated microbiota., Main Outcomes and Measures: The primary outcome was HNSCC incidence., Results: The study included 236 HNSCC case participants with a mean (SD) age of 60.9 (9.5) years and 24.6% women during a mean of 5.1 (3.6) years of follow-up, and 485 matched control participants. Overall microbiome diversity at baseline was not related to subsequent HNSCC risk; however 13 oral bacterial species were found to be differentially associated with development of HNSCC. The species included the newly identified Prevotella salivae, Streptococcus sanguinis, and Leptotrichia species, as well as several species belonging to beta and gamma Proteobacteria. The red/orange periodontal pathogen complex was moderately associated with HNSCC risk (odds ratio, 1.06 per 1 SD; 95% CI, 1.00-1.12). A 1-SD increase in microbial risk score (created based on 22 bacteria) was associated with a 50% increase in HNSCC risk (multivariate odds ratio, 1.50; 95% CI, 1.21-1.85). No fungal taxa associated with HNSCC risk were identified., Conclusions and Relevance: This case-control study yielded compelling evidence that oral bacteria are a risk factor for HNSCC development. The identified bacteria and bacterial complexes hold promise, along with other risk factors, to identify high-risk individuals for personalized prevention of HNSCC.
- Published
- 2024
- Full Text
- View/download PDF
34. Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves cross-ancestry prediction.
- Author
-
Hoffmann TJ, Graff RE, Madduri RK, Rodriguez AA, Cario CL, Feng K, Jiang Y, Wang A, Klein RJ, Pierce BL, Eggener S, Tong L, Blot W, Long J, Goss LB, Darst BF, Rebbeck T, Lachance J, Andrews C, Adebiyi AO, Adusei B, Aisuodionoe-Shadrach OI, Fernandez PW, Jalloh M, Janivara R, Chen WC, Mensah JE, Agalliu I, Berndt SI, Shelley JP, Schaffer K, Machiela MJ, Freedman ND, Huang WY, Li SA, Goodman PJ, Till C, Thompson I, Lilja H, Ranatunga DK, Presti J, Van Den Eeden SK, Chanock SJ, Mosley JD, Conti DV, Haiman CA, Justice AC, Kachuri L, and Witte JS
- Abstract
We conducted a multi-ancestry genome-wide association study of prostate-specific antigen (PSA) levels in 296,754 men (211,342 European ancestry; 58,236 African ancestry; 23,546 Hispanic/Latino; 3,630 Asian ancestry; 96.5% of participants were from the Million Veteran Program). We identified 318 independent genome-wide significant (p≤5e-8) variants, 184 of which were novel. Most demonstrated evidence of replication in an independent cohort (n=95,768). Meta-analyzing discovery and replication (n=392,522) identified 447 variants, of which a further 111 were novel. Out-of-sample variance in PSA explained by our genome-wide polygenic risk scores ranged from 11.6%-16.6% in European ancestry, 5.5%-9.5% in African ancestry, 13.5%-18.2% in Hispanic/Latino, and 8.6%-15.3% in Asian ancestry, and decreased with increasing age. Mid-life genetically-adjusted PSA levels were more strongly associated with overall and aggressive prostate cancer than unadjusted PSA. Our study highlights how including proportionally more participants from underrepresented populations improves genetic prediction of PSA levels, offering potential to personalize prostate cancer screening.
- Published
- 2024
- Full Text
- View/download PDF
35. Frequency of pathogenic germline variants in pediatric medulloblastoma survivors.
- Author
-
Rees D, Gianferante DM, Kim J, Stavrou T, Reaman G, Sapkota Y, Gramatges MM, Morton LM, Hudson MM, Armstrong GT, Freedman ND, Huang WY, Diver WR, Lori A, Luo W, Hicks BD, Liu J, Hutchinson AA, Goldstein AM, and Mirabello L
- Abstract
Background: Medulloblastoma is the most common malignant brain tumor in children. Most cases are sporadic, but well characterized germline alterations in APC , ELP1 , GPR161 , PTCH1 , SUFU , and TP53 predispose to medulloblastoma. However, knowledge about pathogenic/likely pathogenic (P/LP) variants that predispose to medulloblastoma vary based on genes evaluated, patient demographics, and pathogenicity definitions., Methods: Germline exome sequencing was conducted on 160 childhood survivors of medulloblastoma. Analyses focused on rare variants in 239 known cancer susceptibility genes (CSGs). P/LP variants were identified using ClinVar and InterVar. Variants of unknown significance in known medulloblastoma predisposing genes ( APC , ELP1 , GPR161 , PTCH1 , SUFU , TP53) were further classified for loss of function variants. We compared the frequency of P/LP variants in cases to that in 1,259 cancer-free adult controls., Results: Twenty cases (12.5%) had a P/LP variant in an autosomal dominant CSG versus 5% in controls (p=1.0 x10
-3 ), and 10 (6.3%) of these were P/LP variants in a known medulloblastoma gene, significantly greater than 0.2% observed in controls (p=1.4x10-8 ). The CSGs with the most P/LP variants in cases, and significantly higher than controls, were ELP1 ( p=3.0x10-4 ) and SUFU (p=1.4x10-3 )., Conclusion: Approximately one in eight pediatric medulloblastoma survivors had an autosomal dominant P/LP CSG variant. We confirm several known associated genes and identify novel genes that may be important in medulloblastoma., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Rees, Gianferante, Kim, Stavrou, Reaman, Sapkota, Gramatges, Morton, Hudson, Armstrong, Freedman, Huang, Diver, Lori, Luo, Hicks, Liu, Hutchinson, Goldstein and Mirabello.)- Published
- 2024
- Full Text
- View/download PDF
36. Changes in smoking use and subsequent lung cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study.
- Author
-
Gutiérrez-Torres DS, Kim S, Albanes D, Weinstein SJ, Inoue-Choi M, Albert PS, and Freedman ND
- Subjects
- Humans, Middle Aged, Male, Aged, Finland epidemiology, Risk Factors, Smoking Cessation statistics & numerical data, Proportional Hazards Models, Incidence, Lung Neoplasms epidemiology, Lung Neoplasms prevention & control, Lung Neoplasms etiology, beta Carotene administration & dosage, alpha-Tocopherol administration & dosage, Smoking adverse effects, Smoking epidemiology
- Abstract
Background: Reducing cigarettes per day may lower the risk of lung cancer compared with continuing to smoke at the same intensity. Other changes in smoking behaviors, such as increasing cigarette consumption or quitting for a period and relapsing, may also affect lung cancer risk., Methods: We examined changes in smoking status and cigarettes per day among 24 613 Finnish male smokers aged 50-69 years who participated in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Longitudinal data on smoking were collected during study follow-up visits 3 times a year (approximately every 4 months) between 1985 and 1993. Incident lung cancer patients through 2012 were identified by the Finnish Cancer Registry. Risk ratios (RRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression., Results: Compared with smoking 20 cigarettes per day continuously across the intervention period, reducing an average of 5 cigarettes per day per year while smoking was associated with a 20% lower risk of lung cancer (95% CI = 0.71 to 0.90). A substantially lower risk of lung cancer was also observed when participants smoked at 50% (RR = 0.72, 95% CI = 0.57 to 0.90) and 10% (RR = 0.55, 95% CI = 0.36 to 0.83) of study visits, relative to smoked at 100% of study visits., Conclusions: Smokers may lower their risk of lung cancer by reducing smoking intensity (cigarettes per day while smoking) and the time they smoke. However, quitting smoking completely is the most effective way for smokers to reduce their risk of lung cancer., (Published by Oxford University Press 2024.)
- Published
- 2024
- Full Text
- View/download PDF
37. Association of tea and coffee consumption and biliary tract cancer risk: The Biliary Tract Cancers Pooling Project.
- Author
-
Huang YH, Loftfield E, Argirion I, Adami HO, Albanes D, Chan AT, Fedirko V, Fraser GE, Freedman ND, Giles GG, Hartge P, Katzke V, Knutsen SF, Lacey J Jr, Liao LM, Luo J, Milne RL, O'Brien KM, Peters U, Poynter JN, Purdue MP, Robien K, Sandin S, Sandler DP, Setiawan VW, Kang JH, Simon TG, Sinha R, VoPham T, Weinstein SJ, White E, Zhang X, Zhu B, McGlynn KA, Campbell PT, Lee MH, and Koshiol J
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Incidence, Gallbladder Neoplasms epidemiology, Gallbladder Neoplasms etiology, Gallbladder Neoplasms prevention & control, Risk Factors, Adult, Bile Duct Neoplasms epidemiology, Bile Duct Neoplasms etiology, Coffee, Tea, Biliary Tract Neoplasms epidemiology, Biliary Tract Neoplasms etiology
- Abstract
Background and Aims: Tea and coffee are widely consumed beverages worldwide. We evaluated their association with biliary tract cancer (BTC) incidence., Approach and Results: We pooled data from 15 studies in the Biliary Tract Cancers Pooling Project to evaluate associations between tea and coffee consumption and biliary tract cancer development. We categorized participants as nondrinkers (0 cup/day), moderate drinkers (>0 and <3 cups/day), and heavy drinkers (≥3 cups/day). We estimated multivariable HRs and 95% CIs using Cox models. During 29,911,744 person-years of follow-up, 851 gallbladder, 588 intrahepatic bile duct, 753 extrahepatic bile duct, and 458 ampulla of Vater cancer cases were diagnosed. Individuals who drank tea showed a statistically significantly lower incidence rate of gallbladder cancer (GBC) relative to tea nondrinkers (HR=0.77; 95% CI, 0.64-0.91), and intrahepatic bile duct cancer (IHBDC) had an inverse association (HR=0.81; 95% CI, 0.66-1.00). However, no associations were observed for extrahepatic bile duct cancer (EHBDC) or ampulla of Vater cancer (AVC). In contrast, coffee consumption was positively associated with GBC, with a higher incidence rate for individuals consuming more coffee (HR<3 cups/day =1.29; 95% CI, 1.01-1.66; HR≥3 cups/day =1.49; 95% CI, 1.11-1.99, Ptrend=0.01) relative to coffee nondrinkers. However, there was no association between coffee consumption and GBC when restricted to coffee drinkers. There was little evidence of associations between coffee consumption and other biliary tract cancers., Conclusions: Tea consumption was associated with a lower incidence of GBC and possibly IHBDC. Further research is warranted to replicate the observed positive association between coffee and GBC., (Copyright © 2023 American Association for the Study of Liver Diseases.)
- Published
- 2024
- Full Text
- View/download PDF
38. Trends in smoking-attributable and smoking-unrelated lung cancer death rates in the United States, 1991-2018.
- Author
-
Shiels MS, Graubard BI, McNeel TS, Kahle L, and Freedman ND
- Subjects
- Humans, Male, United States epidemiology, Female, Aged, Middle Aged, Adult, Lung Neoplasms mortality, Lung Neoplasms epidemiology, Lung Neoplasms etiology, Smoking adverse effects, Smoking epidemiology
- Abstract
Background: In the United States, lung cancer death rates have been declining for decades, primarily as a result of pronounced decreases in cigarette smoking. It is unclear, however, whether there have been similar declines in mortality rates of lung cancer unrelated to smoking. We estimated trends in US lung cancer death rates attributable and not attributable to smoking from 1991 to 2018., Methods: The study included 30- to 79-year-olds in the National Health Interview Survey who were linked to the National Death Index, 1991-2014. Adjusted hazard ratios for smoking status and lung cancer death were estimated, and age-specific population attributable fractions were calculated. Annual population attributable fractions were multiplied by annual US national lung cancer mortality, partitioning rates into smoking-attributable and smoking-unrelated lung cancer deaths. All statistical tests were 2-sided., Results: During 1991-2018, the proportion of never smokers increased among both men (35.1%-54.6%) and women (54.0%-65.4%). Compared with those who had ever smoked, those who had never smoked had 86% lower risk (hazard ratio = 0.14; 95% confidence interval [CI] = 0.12 to 0.16) of lung cancer death. The fraction of lung cancer deaths attributable to smoking decreased from 81.4% (95% CI = 78.9 to 81.4) to 74.7% (95% CI = 78.1 to 71.4). Smoking-attributable lung cancer death rates declined 2.7% per year (95% CI = ‒2.9% to ‒2.5%) and smoking-unrelated lung cancer death rates declined 1.8% per year (95% CI = ‒2.0% to ‒1.5%); these declines have accelerated in recent years., Conclusions: An increasing proportion of lung cancer deaths are unrelated to smoking based on declines in smoking prevalence. Smoking-unrelated lung cancer death rates have declined, however, perhaps because of decreases in secondhand smoke and air pollution exposure as well as treatment improvements., (Published by Oxford University Press 2023.)
- Published
- 2024
- Full Text
- View/download PDF
39. Exposure to polycyclic aromatic hydrocarbons, volatile organic compounds, and tobacco-specific nitrosamines and incidence of esophageal cancer.
- Author
-
Etemadi A, Poustchi H, Chang CM, Calafat AM, Blount BC, Bhandari D, Wang L, Roshandel G, Alexandridis A, Botelho JC, Xia B, Wang Y, Sosnoff CS, Feng J, Nalini M, Khoshnia M, Pourshams A, Sotoudeh M, Gail MH, Dawsey SM, Kamangar F, Boffetta P, Brennan P, Abnet CC, Malekzadeh R, and Freedman ND
- Subjects
- Humans, Biomarkers, Cohort Studies, Incidence, Esophageal Neoplasms epidemiology, Esophageal Neoplasms etiology, Esophageal Squamous Cell Carcinoma epidemiology, Esophageal Squamous Cell Carcinoma etiology, Nitrosamines, Polycyclic Aromatic Hydrocarbons adverse effects, Volatile Organic Compounds adverse effects
- Abstract
Background: Studying carcinogens in tobacco and nontobacco sources may be key to understanding the pathogenesis and geographic distribution of esophageal cancer., Methods: The Golestan Cohort Study has been conducted since 2004 in a region with high rates of esophageal squamous cell carcinoma. For this nested study, the cases comprised of all incident cases by January 1, 2018; controls were matched to the case by age, sex, residence, time in cohort, and tobacco use. We measured urinary concentrations of 33 exposure biomarkers of nicotine, polycyclic aromatic hydrocarbons, volatile organic compounds, and tobacco-specific nitrosamines. We used conditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals for associations between the 90th vs the 10th percentiles of the biomarker concentrations and incident esophageal squamous cell carcinoma., Results: Among individuals who did not currently use tobacco (148 cases and 163 controls), 2 acrolein metabolites, 2 acrylonitrile metabolites, 1 propylene oxide metabolite, and one 1,3-butadiene metabolite were significantly associated with incident esophageal squamous cell carcinoma (adjusted odds ratios between 1.8 and 4.3). Among tobacco users (57 cases and 63 controls), metabolites of 2 other volatile organic compounds (styrene and xylene) were associated with esophageal squamous cell carcinoma (OR = 6.2 and 9.0, respectively). In tobacco users, 2 tobacco-specific nitrosamines (NNN and N'-Nitrosoanatabine) were also associated with esophageal squamous cell carcinoma. Suggestive associations were seen with some polycyclic aromatic hydrocarbons (especially 2-hydroxynaphthalene) in nonusers of tobacco products and other tobacco-specific nitrosamines in tobacco users., Conclusion: These novel associations based on individual-level data and samples collected many years before cancer diagnosis, from a population without occupational exposure, have important public health implications., (Published by Oxford University Press 2023.)
- Published
- 2024
- Full Text
- View/download PDF
40. Ambient fine particulate matter and breast cancer incidence in a large prospective US cohort.
- Author
-
White AJ, Fisher JA, Sweeney MR, Freedman ND, Kaufman JD, Silverman DT, and Jones RR
- Subjects
- Humans, Female, Particulate Matter adverse effects, Particulate Matter analysis, Prospective Studies, Incidence, Receptors, Estrogen, Environmental Exposure adverse effects, Breast Neoplasms epidemiology, Breast Neoplasms etiology, Air Pollutants adverse effects, Air Pollutants analysis
- Abstract
Background: Fine particulate matter (PM2.5) has been inconsistently associated with breast cancer incidence, however, few studies have considered historic exposure when levels were higher., Methods: Outdoor residential PM2.5 concentrations were estimated using a nationwide spatiotemporal model for women in the National Institutes of Health-AARP Diet and Health Study, a prospective cohort located in 6 states (California, Florida, Louisiana, New Jersey, North Carolina, and Pennsylvania) and 2 metropolitan areas (Atlanta, GA, and Detroit, MI) and enrolled in 1995-1996 (n = 196 905). Annual average PM2.5 concentrations were estimated for a 5-year historical period 10 years prior to enrollment (1980-1984). We used Cox regression to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between a 10 µg/m3 increase in PM2.5 and breast cancer incidence overall and by estrogen receptor status and catchment area., Results: With follow-up of participants through 2017, a total of 15 870 breast cancer cases were identified. A 10 ug/m3 increase in PM2.5 was statistically significantly associated with overall breast cancer incidence (HR = 1.08, 95% CI = 1.02 to 1.13). The association was evident for estrogen receptor-positive (HR = 1.10, 95% CI = 1.04 to 1.17) but not estrogen receptor-negative tumors (HR = 0.97, 95% CI = 0.84 to 1.13; Pheterogeneity = .3). Overall breast cancer hazard ratios were more than 1 across the catchment areas, ranging from a hazard ratio of 1.26 (95% CI = 0.96 to 1.64) for North Carolina to a hazard ratio of 1.04 (95% CI = 0.68 to 1.57) for Louisiana (Pheterogeneity = .9)., Conclusions: In this large US cohort with historical air pollutant exposure estimates, PM2.5 was associated with risk of estrogen receptor-positive breast cancer. State-specific estimates were imprecise but suggest that future work should consider region-specific associations and the potential contribution of PM2.5 chemical constituency in modifying the observed association., (Published by Oxford University Press 2023.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.